ID   NFKB1_HUMAN             Reviewed;         968 AA.
AC   P19838; A8K5Y5; B3KVE8; Q68D84; Q86V43; Q8N4X7; Q9NZC0;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2002, sequence version 2.
DT   28-JUN-2023, entry version 265.
DE   RecName: Full=Nuclear factor NF-kappa-B p105 subunit;
DE   AltName: Full=DNA-binding factor KBF1;
DE   AltName: Full=EBP-1;
DE   AltName: Full=Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1;
DE   Contains:
DE     RecName: Full=Nuclear factor NF-kappa-B p50 subunit;
GN   Name=NFKB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, AND
RP   FUNCTION.
RX   PubMed=2203531; DOI=10.1016/0092-8674(90)90275-j;
RA   Kieran M., Blank V., Logeat F., Vandekerckhove J., Lottspeich F.,
RA   le Bail O., Urban M.B., Kourilsky P., Baeuerle P.A., Israel A.;
RT   "The DNA binding subunit of NF-kappa B is identical to factor KBF1 and
RT   homologous to the rel oncogene product.";
RL   Cell 62:1007-1018(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.
RX   PubMed=2234062; DOI=10.1038/348076a0;
RA   Bours V., Villalobos J., Burd P.R., Kelly K., Siebenlist U.;
RT   "Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein
RT   with homology to the rel oncogene and to cell-cycle motifs.";
RL   Nature 348:76-80(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   INDUCTION.
RX   PubMed=1992489; DOI=10.1073/pnas.88.3.966;
RA   Meyer R., Hatada E.N., Hohmann H.-P., Haiker M., Bartsch C.,
RA   Roethlisberger U., Lahm H.-W., Schlaeger E.J., van Loon A.P.G.M.,
RA   Scheidereit C.;
RT   "Cloning of the DNA-binding subunit of human nuclear factor kappa B: the
RT   level of its mRNA is strongly regulated by phorbol ester or tumor necrosis
RT   factor alpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:966-970(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8825636; DOI=10.1006/geno.1995.1270;
RA   Heron E., Deloukas P., van Loon A.P.G.M.;
RT   "The complete exon-intron structure of the 156-kb human gene NFKB1, which
RT   encodes the p105 and p50 proteins of transcription factors NF-kappa B and I
RT   kappa B-gamma: implications for NF-kappa B-mediated signal transduction.";
RL   Genomics 30:493-505(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chang H.-M., Tsai S.-F.;
RT   "Genome sequencing of the chromosome 4q region implicated in human
RT   hepatocellular carcinoma pathogenesis.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Rectum tumor;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-489; VAL-506; ILE-566;
RP   LYS-578; GLN-711 AND THR-901.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION (NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT), SUBCELLULAR LOCATION
RP   (NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT), AND SUBUNIT (NUCLEAR FACTOR
RP   NF-KAPPA-B P105 SUBUNIT).
RX   PubMed=1423592; DOI=10.1016/0092-8674(92)90353-e;
RA   Rice N.R., MacKichan M.L., Israel A.;
RT   "The precursor of NF-kappa B p50 has I kappa B-like functions.";
RL   Cell 71:243-253(1992).
RN   [11]
RP   IDENTIFICATION IN THE NF-KAPPA-B P65-P50 COMPLEX, AND FUNCTION.
RX   PubMed=1740106; DOI=10.1002/j.1460-2075.1992.tb05043.x;
RA   Hansen S.K., Nerlov C., Zabel U., Verde P., Johnsen M., Baeuerle P.A.,
RA   Blasi F.;
RT   "A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a
RT   DNA element involved in the phorbol ester induction of the human urokinase
RT   gene.";
RL   EMBO J. 11:205-213(1992).
RN   [12]
RP   UBIQUITINATION.
RX   PubMed=8087845; DOI=10.1016/s0092-8674(94)90482-0;
RA   Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T.;
RT   "The ubiquitin-proteasome pathway is required for processing the NF-kappa
RT   B1 precursor protein and the activation of NF-kappa B.";
RL   Cell 78:773-785(1994).
RN   [13]
RP   IDENTIFICATION IN THE NF-KAPPA-B P50-C-REL COMPLEX.
RX   PubMed=8152812;
RA   Beg A.A., Baldwin A.S. Jr.;
RT   "Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor
RT   necrosis factor.";
RL   Oncogene 9:1487-1492(1994).
RN   [14]
RP   PHOSPHORYLATION.
RX   PubMed=8626394; DOI=10.1074/jbc.271.11.6084;
RA   MacKichan M.L., Logeat F., Israel A.;
RT   "Phosphorylation of p105 PEST sequence via a redox-insensitive pathway up-
RT   regulates processing of p50 NF-kappaB.";
RL   J. Biol. Chem. 271:6084-6091(1996).
RN   [15]
RP   PROTEOLYTIC PROCESSING OF P105, AND GENERATION OF P50 AND P105.
RX   PubMed=8628291; DOI=10.1128/mcb.16.5.2248;
RA   Lin L., Ghosh S.;
RT   "A glycine-rich region in NF-kappaB p105 functions as a processing signal
RT   for the generation of the p50 subunit.";
RL   Mol. Cell. Biol. 16:2248-2254(1996).
RN   [16]
RP   S-NITROSYLATION AT CYS-61, MUTAGENESIS OF CYS-61, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=8710491; DOI=10.1093/nar/24.12.2236;
RA   Matthews J.R., Botting C.H., Panico M., Morris H.R., Hay R.T.;
RT   "Inhibition of NF-kappaB DNA binding by nitric oxide.";
RL   Nucleic Acids Res. 24:2236-2242(1996).
RN   [17]
RP   INTERACTION WITH NFKBIE.
RX   PubMed=9315679; DOI=10.1128/mcb.17.10.6184;
RA   Li Z., Nabel G.J.;
RT   "A new member of the IkappaB protein family, IkappaB epsilon, inhibits RelA
RT   (p65)-mediated NF-kappaB transcription.";
RL   Mol. Cell. Biol. 17:6184-6190(1997).
RN   [18]
RP   COTRANSLATIONAL FOLDING/PROCESSING OF P105, AND GENERATION OF P50/P105.
RX   PubMed=9529257; DOI=10.1016/s0092-8674(00)81409-9;
RA   Lin L., DeMartino G.N., Greene W.C.;
RT   "Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome.";
RL   Cell 92:819-828(1998).
RN   [19]
RP   IDENTIFICATION IN A COMPLEX WITH BCL3, AND MUTAGENESIS OF SER-921; SER-923
RP   AND SER-932.
RX   PubMed=10469655; DOI=10.1093/emboj/18.17.4766;
RA   Heissmeyer V., Krappmann D., Wulczyn F.G., Scheidereit C.;
RT   "NF-kappaB p105 is a target of IkappaB kinases and controls signal
RT   induction of Bcl-3-p50 complexes.";
RL   EMBO J. 18:4766-4778(1999).
RN   [20]
RP   INTERACTION WITH MAP3K8.
RX   PubMed=9950430; DOI=10.1038/16946;
RA   Belich M.P., Salmeron A., Johnston L.H., Ley S.C.;
RT   "TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein
RT   NF-kappaB1 p105.";
RL   Nature 397:363-368(1999).
RN   [21]
RP   PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=10835356; DOI=10.1093/emboj/19.11.2580;
RA   Orian A., Gonen H., Bercovich B., Fajerman I., Eytan E., Israel A.,
RA   Mercurio F., Iwai K., Schwartz A.L., Ciechanover A.;
RT   "SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105
RT   requires phosphorylation of its C-terminus by IkappaB kinase.";
RL   EMBO J. 19:2580-2591(2000).
RN   [22]
RP   COTRANSLATIONAL FOLDING/PROCESSING OF P105, GENERATION OF P50/P105, AND
RP   P50-P105 TRANSIENT HETERODIMER FORMATION.
RX   PubMed=10970863; DOI=10.1093/emboj/19.17.4712;
RA   Lin L., DeMartino G.N., Greene W.C.;
RT   "Cotranslational dimerization of the Rel homology domain of NF-kappaB1
RT   generates p50-p105 heterodimers and is required for effective p50
RT   production.";
RL   EMBO J. 19:4712-4722(2000).
RN   [23]
RP   INTERACTION WITH NCOA3.
RX   PubMed=11094166; DOI=10.1016/s0014-5793(00)02223-7;
RA   Werbajh S., Nojek I., Lanz R., Costas M.A.;
RT   "RAC-3 is a NF-kappa B coactivator.";
RL   FEBS Lett. 485:195-199(2000).
RN   [24]
RP   S-NITROSYLATION.
RX   PubMed=11327828; DOI=10.1021/bi002239y;
RA   Marshall H.E., Stamler J.S.;
RT   "Inhibition of NF-kappaB by S-nitrosylation.";
RL   Biochemistry 40:1688-1693(2001).
RN   [25]
RP   INTERACTION WITH TSC22D3.
RX   PubMed=11468175; DOI=10.1182/blood.v98.3.743;
RA   Ayroldi E., Migliorati G., Bruscoli S., Marchetti C., Zollo O.,
RA   Cannarile L., D'Adamio F., Riccardi C.;
RT   "Modulation of T-cell activation by the glucocorticoid-induced leucine
RT   zipper factor via inhibition of nuclear factor kappa B.";
RL   Blood 98:743-753(2001).
RN   [26]
RP   LIPIDATION AT CYS-61, AND MUTAGENESIS OF CYS-61.
RX   PubMed=11466314; DOI=10.1074/jbc.m104518200;
RA   Cernuda-Morollon E., Pineda-Molina E., Canada F.J., Perez-Sala D.;
RT   "15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding
RT   through covalent modification of the p50 subunit.";
RL   J. Biol. Chem. 276:35530-35536(2001).
RN   [27]
RP   PHOSPHORYLATION AT SER-927.
RX   PubMed=11297557; DOI=10.1074/jbc.m101754200;
RA   Salmeron A., Janzen J., Soneji Y., Bump N., Kamens J., Allen H., Ley S.C.;
RT   "Direct phosphorylation of NF-kappa B1 p105 by the Ikappa B kinase complex
RT   on serine 927 is essential for signal-induced p105 proteolysis.";
RL   J. Biol. Chem. 276:22215-22222(2001).
RN   [28]
RP   UBIQUITINATION, AND PHOSPHORYLATION AT SER-923 AND SER-927.
RX   PubMed=11158290; DOI=10.1128/mcb.21.4.1024-1035.2001;
RA   Heissmeyer V., Krappmann D., Hatada E.N., Scheidereit C.;
RT   "Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated
RT   ubiquitination and degradation for the NF-kappaB precursor p105 and
RT   IkappaBalpha.";
RL   Mol. Cell. Biol. 21:1024-1035(2001).
RN   [29]
RP   INTERACTION WITH MEN1.
RX   PubMed=11526476; DOI=10.1038/sj.onc.1204529;
RA   Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J.,
RA   Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J.,
RA   Burns A.L.;
RT   "The tumor suppressor protein menin interacts with NF-kappaB proteins and
RT   inhibits NF-kappaB-mediated transactivation.";
RL   Oncogene 20:4917-4925(2001).
RN   [30]
RP   INTERACTION WITH CFLAR.
RX   PubMed=13679070; DOI=10.1016/j.bbrc.2003.08.104;
RA   Li Z., Zhang J., Chen D., Shu H.B.;
RT   "Casper/c-FLIP is physically and functionally associated with NF-kappaB1
RT   p105.";
RL   Biochem. Biophys. Res. Commun. 309:980-985(2003).
RN   [31]
RP   ACETYLATION AT LYS-431; LYS-440 AND LYS-441.
RX   PubMed=11739381; DOI=10.1074/jbc.m107848200;
RA   Furia B., Deng L., Wu K., Baylor S., Kehn K., Li H., Donnelly R.,
RA   Coleman T., Kashanchi F.;
RT   "Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and
RT   HIV-1 Tat proteins.";
RL   J. Biol. Chem. 277:4973-4980(2002).
RN   [32]
RP   INTERACTION WITH TSC22D3.
RX   PubMed=12393603; DOI=10.1182/blood-2002-02-0538;
RA   Berrebi D., Bruscoli S., Cohen N., Foussat A., Migliorati G.,
RA   Bouchet-Delbos L., Maillot M.-C., Portier A., Couderc J., Galanaud P.,
RA   Peuchmaur M., Riccardi C., Emilie D.;
RT   "Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages:
RT   an anti-inflammatory and immunosuppressive mechanism shared by
RT   glucocorticoids and IL-10.";
RL   Blood 101:729-738(2003).
RN   [33]
RP   ACETYLATION.
RX   PubMed=12471036; DOI=10.1074/jbc.m209286200;
RA   Deng W.G., Zhu Y., Wu K.K.;
RT   "Up-regulation of p300 binding and p50 acetylation in tumor necrosis
RT   factor-alpha-induced cyclooxygenase-2 promoter activation.";
RL   J. Biol. Chem. 278:4770-4777(2003).
RN   [34]
RP   INTERACTION WITH GSK3B, PHOSPHORYLATION AT SER-903 AND SER-907, AND
RP   MUTAGENESIS OF SER-903 AND SER-907.
RX   PubMed=12871932; DOI=10.1074/jbc.m305676200;
RA   Demarchi F., Bertoli C., Sandy P., Schneider C.;
RT   "Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability.";
RL   J. Biol. Chem. 278:39583-39590(2003).
RN   [35]
RP   PHOSPHORYLATION AT SER-927 AND SER-932.
RX   PubMed=12482991; DOI=10.1128/mcb.23.1.402-413.2003;
RA   Lang V., Janzen J., Fischer G.Z., Soneji Y., Beinke S., Salmeron A.,
RA   Allen H., Hay R.T., Ben-Neriah Y., Ley S.C.;
RT   "betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation
RT   of p105 serines 927 and 932.";
RL   Mol. Cell. Biol. 23:402-413(2003).
RN   [36]
RP   INTERACTION WITH UNC5CL.
RX   PubMed=14769797; DOI=10.1074/jbc.m310737200;
RA   Zhang J., Xu L.-G., Han K.-J., Shu H.-B.;
RT   "Identification of a ZU5 and death domain-containing inhibitor of NF-
RT   kappaB.";
RL   J. Biol. Chem. 279:17819-17825(2004).
RN   [37]
RP   PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=14673179; DOI=10.1128/mcb.24.1.475-486.2004;
RA   Cohen S., Achbert-Weiner H., Ciechanover A.;
RT   "Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 fate:
RT   SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent
RT   processing.";
RL   Mol. Cell. Biol. 24:475-486(2004).
RN   [38]
RP   INTERACTION WITH MAP3K8 AND TNIP2.
RX   PubMed=15169888; DOI=10.1128/mcb.24.12.5235-5248.2004;
RA   Lang V., Symons A., Watton S.J., Janzen J., Soneji Y., Beinke S.,
RA   Howell S., Ley S.C.;
RT   "ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is
RT   essential for TPL-2 protein stability.";
RL   Mol. Cell. Biol. 24:5235-5248(2004).
RN   [39]
RP   IDENTIFICATION IN THE NF-KAPPA-B P50-C-REL COMPLEX.
RX   PubMed=15102766; DOI=10.1128/iai.72.5.2582-2589.2004;
RA   Guizani-Tabbane L., Ben-Aissa K., Belghith M., Sassi A., Dellagi K.;
RT   "Leishmania major amastigotes induce p50/c-Rel NF-kappa B transcription
RT   factor in human macrophages: involvement in cytokine synthesis.";
RL   Infect. Immun. 72:2582-2589(2004).
RN   [40]
RP   FUNCTION, AND INTERACTION WITH MAP3K8.
RX   PubMed=15485931; DOI=10.1128/mcb.24.21.9658-9667.2004;
RA   Beinke S., Robinson M.J., Hugunin M., Ley S.C.;
RT   "Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-
RT   regulated kinase mitogen-activated protein kinase cascade is regulated by
RT   IkappaB kinase-induced proteolysis of NF-kappaB1 p105.";
RL   Mol. Cell. Biol. 24:9658-9667(2004).
RN   [41]
RP   INTERACTION WITH SPAG9.
RX   PubMed=14743216; DOI=10.1038/ncb1086;
RA   Bouwmeester T., Bauch A., Ruffner H., Angrand P.-O., Bergamini G.,
RA   Croughton K., Cruciat C., Eberhard D., Gagneur J., Ghidelli S., Hopf C.,
RA   Huhse B., Mangano R., Michon A.-M., Schirle M., Schlegl J., Schwab M.,
RA   Stein M.A., Bauer A., Casari G., Drewes G., Gavin A.-C., Jackson D.B.,
RA   Joberty G., Neubauer G., Rick J., Kuster B., Superti-Furga G.;
RT   "A physical and functional map of the human TNF-alpha/NF-kappa B signal
RT   transduction pathway.";
RL   Nat. Cell Biol. 6:97-105(2004).
RN   [42]
RP   INTERACTION WITH HIF1AN, HYDROXYLATION AT ASN-678, AND MUTAGENESIS OF
RP   ASN-678.
RX   PubMed=17003112; DOI=10.1073/pnas.0606877103;
RA   Cockman M.E., Lancaster D.E., Stolze I.P., Hewitson K.S., McDonough M.A.,
RA   Coleman M.L., Coles C.H., Yu X., Hay R.T., Ley S.C., Pugh C.W.,
RA   Oldham N.J., Masson N., Schofield C.J., Ratcliffe P.J.;
RT   "Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by
RT   the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor
RT   inhibiting HIF (FIH).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:14767-14772(2006).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-937, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-903 AND SER-907, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-892, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [48]
RP   INVOLVEMENT IN CVID12.
RX   PubMed=26279205; DOI=10.1016/j.ajhg.2015.07.008;
RA   Fliegauf M., Bryant V.L., Frede N., Slade C., Woon S.T., Lehnert K.,
RA   Winzer S., Bulashevska A., Scerri T., Leung E., Jordan A., Keller B.,
RA   de Vries E., Cao H., Yang F., Schaeffer A.A., Warnatz K., Browett P.,
RA   Douglass J., Ameratunga R.V., van der Meer J.W., Grimbacher B.;
RT   "Haploinsufficiency of the NF-kappaB1 Subunit p50 in Common Variable
RT   Immunodeficiency.";
RL   Am. J. Hum. Genet. 97:389-403(2015).
RN   [49]
RP   PROTEOLYTIC PROCESSING OF P105, GENERATION OF P50 AND P105, UBIQUITINATION,
RP   PHOSPHORYLATION AT SER-927, AND MUTAGENESIS OF SER-927.
RX   PubMed=25860612; DOI=10.1016/j.cell.2015.03.001;
RA   Kravtsova-Ivantsiv Y., Shomer I., Cohen-Kaplan V., Snijder B.,
RA   Superti-Furga G., Gonen H., Sommer T., Ziv T., Admon A., Naroditsky I.,
RA   Jbara M., Brik A., Pikarsky E., Kwon Y.T., Doweck I., Ciechanover A.;
RT   "KPC1-mediated ubiquitination and proteasomal processing of NF-kappaB1 p105
RT   to p50 restricts tumor growth.";
RL   Cell 161:333-347(2015).
RN   [50]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-325, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-365, FUNCTION, AND SUBUNIT.
RX   PubMed=7830764; DOI=10.1038/373311a0;
RA   Mueller C.W., Rey F.A., Sodeoka M., Verdine G.L., Harrison S.C.;
RT   "Structure of the NF-kappa B p50 homodimer bound to DNA.";
RL   Nature 373:311-317(1995).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 248-354, AND SUBCELLULAR LOCATION.
RX   PubMed=9865693; DOI=10.1016/s0092-8674(00)81698-0;
RA   Jacobs M.D., Harrison S.C.;
RT   "Structure of an IkappaBalpha/NF-kappaB complex.";
RL   Cell 95:749-758(1998).
RN   [53]
RP   STRUCTURE BY NMR OF 804-893.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the death domain in human nuclear factor NF-kappa-B
RT   p105 subunit.";
RL   Submitted (DEC-2006) to the PDB data bank.
CC   -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in
CC       almost all cell types and is the endpoint of a series of signal
CC       transduction events that are initiated by a vast array of stimuli
CC       related to many biological processes such as inflammation, immunity,
CC       differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B
CC       is a homo- or heterodimeric complex formed by the Rel-like domain-
CC       containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and
CC       NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most
CC       abundant one. The dimers bind at kappa-B sites in the DNA of their
CC       target genes and the individual dimers have distinct preferences for
CC       different kappa-B sites that they can bind with distinguishable
CC       affinity and specificity. Different dimer combinations act as
CC       transcriptional activators or repressors, respectively. NF-kappa-B is
CC       controlled by various mechanisms of post-translational modification and
CC       subcellular compartmentalization as well as by interactions with other
CC       cofactors or corepressors. NF-kappa-B complexes are held in the
CC       cytoplasm in an inactive state complexed with members of the NF-kappa-B
CC       inhibitor (I-kappa-B) family. In a conventional activation pathway, I-
CC       kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to
CC       different activators, subsequently degraded thus liberating the active
CC       NF-kappa-B complex which translocates to the nucleus. NF-kappa-B
CC       heterodimeric p65-p50 and RelB-p50 complexes are transcriptional
CC       activators. The NF-kappa-B p50-p50 homodimer is a transcriptional
CC       repressor, but can act as a transcriptional activator when associated
CC       with BCL3. NFKB1 appears to have dual functions such as cytoplasmic
CC       retention of attached NF-kappa-B proteins by p105 and generation of p50
CC       by a cotranslational processing. The proteasome-mediated process
CC       ensures the production of both p50 and p105 and preserves their
CC       independent function, although processing of NFKB1/p105 also appears to
CC       occur post-translationally. p50 binds to the kappa-B consensus sequence
CC       5'-GGRNNYYCC-3', located in the enhancer region of genes involved in
CC       immune response and acute phase reactions. In a complex with MAP3K8,
CC       NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is
CC       released by proteasome-dependent degradation of NFKB1/p105.
CC       {ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:1740106,
CC       ECO:0000269|PubMed:2203531, ECO:0000269|PubMed:2234062,
CC       ECO:0000269|PubMed:7830764}.
CC   -!- FUNCTION: [Nuclear factor NF-kappa-B p105 subunit]: P105 is the
CC       precursor of the active p50 subunit (Nuclear factor NF-kappa-B p50
CC       subunit) of the nuclear factor NF-kappa-B (PubMed:1423592). Acts as a
CC       cytoplasmic retention of attached NF-kappa-B proteins by p105
CC       (PubMed:1423592). {ECO:0000269|PubMed:1423592}.
CC   -!- FUNCTION: [Nuclear factor NF-kappa-B p50 subunit]: Constitutes the
CC       active form, which associates with RELA/p65 to form the NF-kappa-B p65-
CC       p50 complex to form a transcription factor (PubMed:1740106,
CC       PubMed:7830764). Together with RELA/p65, binds to the kappa-B consensus
CC       sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes
CC       involved in immune response and acute phase reactions (PubMed:1740106,
CC       PubMed:7830764). {ECO:0000269|PubMed:1740106,
CC       ECO:0000269|PubMed:7830764}.
CC   -!- SUBUNIT: Component of the NF-kappa-B p65-p50 complex (PubMed:1740106,
CC       PubMed:7830764). Homodimer; component of the NF-kappa-B p50-p50
CC       complex. Component of the NF-kappa-B p105-p50 complex (PubMed:1423592).
CC       Component of the NF-kappa-B p50-c-Rel complex (PubMed:15102766,
CC       PubMed:8152812). Component of a complex consisting of the NF-kappa-B
CC       p50-p50 homodimer and BCL3 (PubMed:10469655). Also interacts with
CC       MAP3K8 (PubMed:9950430, PubMed:15485931). NF-kappa-B p50 subunit
CC       interacts with NCOA3 coactivator, which may coactivate NF-kappa-B
CC       dependent expression via its histone acetyltransferase activity
CC       (PubMed:11094166). Interacts with TSC22D3; this interaction prevents
CC       nuclear translocation and DNA-binding (PubMed:11468175,
CC       PubMed:12393603). Interacts with SPAG9 and UNC5CL (PubMed:14769797,
CC       PubMed:14743216). NFKB1/p105 interacts with CFLAR; the interaction
CC       inhibits p105 processing into p50 (PubMed:13679070). NFKB1/p105 forms a
CC       ternary complex with MAP3K8 and TNIP2 (PubMed:15169888). Interacts with
CC       GSK3B; the interaction prevents processing of p105 to p50
CC       (PubMed:12871932). NFKB1/p50 interacts with NFKBIE (PubMed:9315679).
CC       NFKB1/p50 interacts with NFKBIZ (By similarity). Nuclear factor NF-
CC       kappa-B p50 subunit interacts with NFKBID (By similarity). Directly
CC       interacts with MEN1 (PubMed:11526476). Interacts with HIF1AN
CC       (PubMed:17003112). Interacts with FEM1A; interaction is direct (By
CC       similarity). {ECO:0000250|UniProtKB:P25799,
CC       ECO:0000269|PubMed:10469655, ECO:0000269|PubMed:11094166,
CC       ECO:0000269|PubMed:11468175, ECO:0000269|PubMed:11526476,
CC       ECO:0000269|PubMed:12393603, ECO:0000269|PubMed:12871932,
CC       ECO:0000269|PubMed:13679070, ECO:0000269|PubMed:1423592,
CC       ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,
CC       ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,
CC       ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,
CC       ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:7830764,
CC       ECO:0000269|PubMed:8152812, ECO:0000269|PubMed:9315679,
CC       ECO:0000269|PubMed:9950430}.
CC   -!- INTERACTION:
CC       P19838; Q92887: ABCC2; NbExp=3; IntAct=EBI-300010, EBI-3916193;
CC       P19838; O15111: CHUK; NbExp=3; IntAct=EBI-300010, EBI-81249;
CC       P19838; P35606: COPB2; NbExp=5; IntAct=EBI-300010, EBI-1056534;
CC       P19838; P35222: CTNNB1; NbExp=3; IntAct=EBI-300010, EBI-491549;
CC       P19838; Q13547: HDAC1; NbExp=5; IntAct=EBI-300010, EBI-301834;
CC       P19838; Q9NWT6: HIF1AN; NbExp=7; IntAct=EBI-300010, EBI-745632;
CC       P19838; O14920: IKBKB; NbExp=3; IntAct=EBI-300010, EBI-81266;
CC       P19838; P41279: MAP3K8; NbExp=14; IntAct=EBI-300010, EBI-354900;
CC       P19838; P19838: NFKB1; NbExp=7; IntAct=EBI-300010, EBI-300010;
CC       P19838; Q00653: NFKB2; NbExp=8; IntAct=EBI-300010, EBI-307326;
CC       P19838; P25963: NFKBIA; NbExp=8; IntAct=EBI-300010, EBI-307386;
CC       P19838; Q15653: NFKBIB; NbExp=3; IntAct=EBI-300010, EBI-352889;
CC       P19838; P46531: NOTCH1; NbExp=2; IntAct=EBI-300010, EBI-636374;
CC       P19838; Q14690: PDCD11; NbExp=2; IntAct=EBI-300010, EBI-300028;
CC       P19838; Q8IZL8: PELP1; NbExp=2; IntAct=EBI-300010, EBI-716449;
CC       P19838; Q8IV08: PLD3; NbExp=2; IntAct=EBI-300010, EBI-2689908;
CC       P19838; Q04206: RELA; NbExp=14; IntAct=EBI-300010, EBI-73886;
CC       P19838; Q01201: RELB; NbExp=5; IntAct=EBI-300010, EBI-357837;
CC       P19838; P23396: RPS3; NbExp=4; IntAct=EBI-300010, EBI-351193;
CC       P19838; Q15025: TNIP1; NbExp=5; IntAct=EBI-300010, EBI-357849;
CC       P19838; Q8NFZ5: TNIP2; NbExp=7; IntAct=EBI-300010, EBI-359372;
CC       P19838; P10226: UL42; Xeno; NbExp=4; IntAct=EBI-300010, EBI-1029310;
CC       P19838-1; Q8NFZ5: TNIP2; NbExp=8; IntAct=EBI-1452239, EBI-359372;
CC       P19838-2; P42858: HTT; NbExp=3; IntAct=EBI-1452242, EBI-466029;
CC       PRO_0000030311; P03372: ESR1; NbExp=3; IntAct=EBI-697771, EBI-78473;
CC       PRO_0000030311; O00255: MEN1; NbExp=2; IntAct=EBI-697771, EBI-592789;
CC       PRO_0000030311; O00255-2: MEN1; NbExp=4; IntAct=EBI-697771, EBI-9869387;
CC       PRO_0000030311; Q04206: RELA; NbExp=7; IntAct=EBI-697771, EBI-73886;
CC       PRO_0000030311; P10226: UL42; Xeno; NbExp=2; IntAct=EBI-697771, EBI-1029310;
CC   -!- SUBCELLULAR LOCATION: [Nuclear factor NF-kappa-B p105 subunit]:
CC       Cytoplasm {ECO:0000269|PubMed:1423592}.
CC   -!- SUBCELLULAR LOCATION: [Nuclear factor NF-kappa-B p50 subunit]: Nucleus
CC       {ECO:0000269|PubMed:9865693}. Cytoplasm {ECO:0000269|PubMed:9865693}.
CC       Note=Association with NFKBIA inhibitor (I-kappa-B), promotes its
CC       retention in the cytoplasm in an inactive form (PubMed:9865693).
CC       Translocates into the nucleus following NFKBIA degradation
CC       (PubMed:9865693). {ECO:0000269|PubMed:9865693}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P19838-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19838-2; Sequence=VSP_021025;
CC       Name=3;
CC         IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;
CC   -!- INDUCTION: By phorbol ester and TNF. {ECO:0000269|PubMed:1992489}.
CC   -!- DOMAIN: The C-terminus of p105 might be involved in cytoplasmic
CC       retention, inhibition of DNA-binding, and transcription activation.
CC       {ECO:0000269|PubMed:1423592}.
CC   -!- DOMAIN: Glycine-rich region (GRR) is a critical element in the
CC       generation of p50 (Nuclear factor NF-kappa-B p50 subunit) by acting as
CC       a proteasomal 'stop signal', which leads to limited proteasomal
CC       degradation of the C-terminus, while generating p50.
CC       {ECO:0000269|PubMed:8628291, ECO:0000269|PubMed:9529257}.
CC   -!- PTM: Generation of the NF-kappa-B p50 (Nuclear factor NF-kappa-B p50
CC       subunit) transcription factor takes place both cotranslationally and
CC       post-translationally via non-mutually exclusive mechanisms
CC       (PubMed:8628291, PubMed:9529257, PubMed:10970863, PubMed:25860612). A
CC       cotranslational processing allows the production of both p50 and p105
CC       (Nuclear factor NF-kappa-B p105 subunit) from a single NFKB1 mRNA
CC       (PubMed:8628291, PubMed:9529257, PubMed:10970863). While translation
CC       occurs, the particular unfolded structure after the GRR repeat region
CC       acts as a substrate for the proteasome, promoting degradation of the C-
CC       terminus (PubMed:9529257, PubMed:10970863). The GRR acts as a
CC       proteasomal 'stop signal', protecting the region upstream of the GRR
CC       from degradation and promoting generation of p50 (PubMed:9529257,
CC       PubMed:10970863). It is unclear if limited proteasome degradation
CC       during cotranslational processing depends on ubiquitination
CC       (PubMed:9529257, PubMed:10970863). NF-kappa-B p50 is also generated
CC       post-translationally following ubiquitination by the KPC complex,
CC       leading to limited processing by the proteasome downstream of the GRR
CC       region, thereby generating p50 (PubMed:25860612).
CC       {ECO:0000269|PubMed:10970863, ECO:0000269|PubMed:25860612,
CC       ECO:0000269|PubMed:8628291, ECO:0000269|PubMed:9529257}.
CC   -!- PTM: [Nuclear factor NF-kappa-B p105 subunit]: Phosphorylation at the
CC       C-terminus by IKBKB/IKKB acts as a signal for ubiquitination and
CC       promotes either complete degradation or processing to generate the NF-
CC       kappa-B p50 (Nuclear factor NF-kappa-B p50 subunit) (PubMed:8626394,
CC       PubMed:10835356, PubMed:11297557, PubMed:11158290, PubMed:12482991,
CC       PubMed:14673179, PubMed:25860612). Phosphorylation at Ser-903 and Ser-
CC       907 primes p105 for proteolytic processing in response to TNF-alpha
CC       stimulation (PubMed:12871932). Phosphorylation at Ser-923, Ser-927 and
CC       Ser-932 are required for BTRC/BTRCP-mediated ubiquitination and
CC       proteolysis (PubMed:10835356, PubMed:11297557, PubMed:11158290,
CC       PubMed:12482991, PubMed:14673179). Phosphorylation at Ser-927 is also
CC       required for ubiquitination by the KPC complex and limited processing
CC       to generate NF-kappa-B p50 (Nuclear factor NF-kappa-B p50 subunit)
CC       (PubMed:25860612). {ECO:0000269|PubMed:10835356,
CC       ECO:0000269|PubMed:11158290, ECO:0000269|PubMed:11297557,
CC       ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,
CC       ECO:0000269|PubMed:14673179, ECO:0000269|PubMed:25860612,
CC       ECO:0000269|PubMed:8626394}.
CC   -!- PTM: [Nuclear factor NF-kappa-B p105 subunit]: Polyubiquitinated at
CC       multiple Lys residues in the C-terminus (PubMed:11158290,
CC       PubMed:14673179, PubMed:25860612). Polyubiquitinated by the SCF(FBXW11)
CC       and SCF(BTRC) complexes following phosphorylation at Ser-923, Ser-927
CC       and Ser-932, leading to its complete degradation (PubMed:11158290). In
CC       contrast, polyubiquitination by the KPC complex following
CC       phosphorylation at Ser-927 leads to limited proteosomal processing and
CC       generation of the active NF-kappa-B p50 (Nuclear factor NF-kappa-B p50
CC       subunit) (PubMed:25860612). {ECO:0000269|PubMed:11158290,
CC       ECO:0000269|PubMed:14673179, ECO:0000269|PubMed:25860612}.
CC   -!- PTM: S-nitrosylation of Cys-61 affects DNA binding.
CC       {ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.
CC   -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-
CC       prostaglandin-J2 is autocatalytic and reversible. It may occur as an
CC       alternative to other cysteine modifications, such as S-nitrosylation
CC       and S-palmitoylation. {ECO:0000269|PubMed:11466314}.
CC   -!- DISEASE: Immunodeficiency, common variable, 12, with autoimmunity
CC       (CVID12) [MIM:616576]: A primary immunodeficiency characterized by
CC       hypogammaglobulinemia and recurrent bacterial infections. About half of
CC       patients develop autoimmune features, including cytopenia, as well as
CC       generalized inflammation and lymphoproliferation manifest as
CC       lymphadenopathy or hepatosplenomegaly. {ECO:0000269|PubMed:26279205}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/323/NFKB1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nfkb1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55643; AAA36361.1; -; mRNA.
DR   EMBL; M58603; AAA36360.1; -; mRNA.
DR   EMBL; Z47748; CAB94757.1; -; Genomic_DNA.
DR   EMBL; Z47749; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47750; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47751; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47752; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47753; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47754; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47755; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47734; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47735; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47736; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47737; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47738; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47739; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47740; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47741; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47742; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47743; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; Z47744; CAB94757.1; JOINED; Genomic_DNA.
DR   EMBL; AF213884; AAF35232.1; -; Genomic_DNA.
DR   EMBL; AK122850; BAG53760.1; -; mRNA.
DR   EMBL; AK291450; BAF84139.1; -; mRNA.
DR   EMBL; CR749522; CAH18336.1; -; mRNA.
DR   EMBL; AY223820; AAO30127.1; -; Genomic_DNA.
DR   EMBL; BC033210; AAH33210.1; -; mRNA.
DR   EMBL; BC051765; AAH51765.1; -; mRNA.
DR   CCDS; CCDS3657.1; -. [P19838-2]
DR   CCDS; CCDS54783.1; -. [P19838-1]
DR   PIR; A37867; A37867.
DR   RefSeq; NP_001158884.1; NM_001165412.1. [P19838-1]
DR   RefSeq; NP_001306155.1; NM_001319226.1. [P19838-1]
DR   RefSeq; NP_003989.2; NM_003998.3. [P19838-2]
DR   PDB; 1MDI; NMR; -; B=55-67.
DR   PDB; 1MDJ; NMR; -; B=55-67.
DR   PDB; 1MDK; NMR; -; B=55-67.
DR   PDB; 1NFI; X-ray; 2.70 A; B/D=248-354.
DR   PDB; 1SVC; X-ray; 2.60 A; P=2-365.
DR   PDB; 2DBF; NMR; -; A=806-893.
DR   PDB; 2O61; X-ray; 2.80 A; B=40-352.
DR   PDB; 3GUT; X-ray; 3.59 A; B/D/F/H=41-352.
DR   PDB; 7LEQ; X-ray; 2.24 A; B=355-368.
DR   PDB; 7LET; X-ray; 2.40 A; B=355-368.
DR   PDB; 7LF4; X-ray; 2.85 A; B/F=355-368.
DR   PDB; 7LFC; X-ray; 2.10 A; B=355-368.
DR   PDB; 7RG4; X-ray; 2.60 A; B=331-370.
DR   PDB; 7RG5; X-ray; 2.15 A; B=331-370.
DR   PDBsum; 1MDI; -.
DR   PDBsum; 1MDJ; -.
DR   PDBsum; 1MDK; -.
DR   PDBsum; 1NFI; -.
DR   PDBsum; 1SVC; -.
DR   PDBsum; 2DBF; -.
DR   PDBsum; 2O61; -.
DR   PDBsum; 3GUT; -.
DR   PDBsum; 7LEQ; -.
DR   PDBsum; 7LET; -.
DR   PDBsum; 7LF4; -.
DR   PDBsum; 7LFC; -.
DR   PDBsum; 7RG4; -.
DR   PDBsum; 7RG5; -.
DR   AlphaFoldDB; P19838; -.
DR   SMR; P19838; -.
DR   BioGRID; 110857; 293.
DR   ComplexPortal; CPX-5828; NF-kappaB DNA-binding transcription factor complex, p50/p65.
DR   ComplexPortal; CPX-5832; NF-kappaB DNA-binding transcription factor complex, p50/c-Rel.
DR   ComplexPortal; CPX-5833; NF-kappaB DNA-binding transcription factor complex, p50/RelB.
DR   ComplexPortal; CPX-5837; NF-kappaB transcription regulation complex, p50/p52.
DR   ComplexPortal; CPX-5838; NF-kappaB transcription regulation complex, p50/p50.
DR   CORUM; P19838; -.
DR   DIP; DIP-106N; -.
DR   ELM; P19838; -.
DR   IntAct; P19838; 498.
DR   MINT; P19838; -.
DR   STRING; 9606.ENSP00000226574; -.
DR   BindingDB; P19838; -.
DR   ChEMBL; CHEMBL3251; -.
DR   DrugBank; DB05767; Andrographolide.
DR   DrugBank; DB05487; Custirsen.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB13961; Fish oil.
DR   DrugBank; DB13751; Glycyrrhizic acid.
DR   DrugBank; DB05212; HE3286.
DR   DrugBank; DB05559; NF-kappaB Decoy.
DR   DrugBank; DB05464; NOX-700.
DR   DrugBank; DB05451; P54.
DR   DrugBank; DB01411; Pranlukast.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   DrugBank; DB14059; SC-236.
DR   DrugBank; DB05471; SGN-30.
DR   DrugBank; DB00795; Sulfasalazine.
DR   DrugBank; DB12816; Terpinen-4-ol.
DR   DrugBank; DB08814; Triflusal.
DR   DrugCentral; P19838; -.
DR   GlyCosmos; P19838; 2 sites, 1 glycan.
DR   GlyGen; P19838; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; P19838; -.
DR   MetOSite; P19838; -.
DR   PhosphoSitePlus; P19838; -.
DR   BioMuta; NFKB1; -.
DR   DMDM; 21542418; -.
DR   CPTAC; CPTAC-1260; -.
DR   CPTAC; CPTAC-1330; -.
DR   EPD; P19838; -.
DR   jPOST; P19838; -.
DR   MassIVE; P19838; -.
DR   MaxQB; P19838; -.
DR   PaxDb; P19838; -.
DR   PeptideAtlas; P19838; -.
DR   ProteomicsDB; 53694; -. [P19838-1]
DR   ProteomicsDB; 53695; -. [P19838-2]
DR   ProteomicsDB; 53696; -. [P19838-3]
DR   Antibodypedia; 3415; 2696 antibodies from 51 providers.
DR   DNASU; 4790; -.
DR   Ensembl; ENST00000226574.9; ENSP00000226574.4; ENSG00000109320.14. [P19838-2]
DR   Ensembl; ENST00000394820.8; ENSP00000378297.4; ENSG00000109320.14. [P19838-1]
DR   Ensembl; ENST00000505458.5; ENSP00000424790.1; ENSG00000109320.14. [P19838-1]
DR   Ensembl; ENST00000509165.2; ENSP00000423877.2; ENSG00000109320.14. [P19838-2]
DR   GeneID; 4790; -.
DR   KEGG; hsa:4790; -.
DR   MANE-Select; ENST00000226574.9; ENSP00000226574.4; NM_003998.4; NP_003989.2. [P19838-2]
DR   UCSC; uc011cep.2; human. [P19838-1]
DR   AGR; HGNC:7794; -.
DR   CTD; 4790; -.
DR   DisGeNET; 4790; -.
DR   GeneCards; NFKB1; -.
DR   HGNC; HGNC:7794; NFKB1.
DR   HPA; ENSG00000109320; Low tissue specificity.
DR   MalaCards; NFKB1; -.
DR   MIM; 164011; gene.
DR   MIM; 616576; phenotype.
DR   neXtProt; NX_P19838; -.
DR   OpenTargets; ENSG00000109320; -.
DR   Orphanet; 1572; Common variable immunodeficiency.
DR   PharmGKB; PA248; -.
DR   VEuPathDB; HostDB:ENSG00000109320; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   GeneTree; ENSGT00940000158625; -.
DR   HOGENOM; CLU_004343_1_0_1; -.
DR   InParanoid; P19838; -.
DR   OMA; GCSPNQQ; -.
DR   OrthoDB; 1059550at2759; -.
DR   PhylomeDB; P19838; -.
DR   TreeFam; TF325632; -.
DR   PathwayCommons; P19838; -.
DR   Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-193692; Regulated proteolysis of p75NTR.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-209560; NF-kB is activated and signals survival.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-3134963; DEx/H-box helicases activate type I IFN and inflammatory cytokines production.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-448706; Interleukin-1 processing.
DR   Reactome; R-HSA-5603029; IkBA variant leads to EDA-ID.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5660668; CLEC7A/inflammasome pathway.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-844456; The NLRP3 inflammasome.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   Reactome; R-HSA-9660826; Purinergic signaling in leishmaniasis infection.
DR   Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses.
DR   SignaLink; P19838; -.
DR   SIGNOR; P19838; -.
DR   BioGRID-ORCS; 4790; 25 hits in 1191 CRISPR screens.
DR   ChiTaRS; NFKB1; human.
DR   EvolutionaryTrace; P19838; -.
DR   GeneWiki; NFKB1; -.
DR   GenomeRNAi; 4790; -.
DR   Pharos; P19838; Tclin.
DR   PRO; PR:P19838; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P19838; protein.
DR   Bgee; ENSG00000109320; Expressed in endometrium epithelium and 160 other tissues.
DR   ExpressionAtlas; P19838; baseline and differential.
DR   Genevisible; P19838; HS.
DR   GO; GO:0000785; C:chromatin; IDA:UniProt.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0033256; C:I-kappaB/NF-kappaB complex; TAS:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0071159; C:NF-kappaB complex; IPI:ComplexPortal.
DR   GO; GO:0035525; C:NF-kappaB p50/p65 complex; NAS:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:0042805; F:actinin binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IMP:BHF-UCL.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:MGI.
DR   GO; GO:0019899; F:enzyme binding; IPI:ARUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:ARUK-UCL.
DR   GO; GO:0003712; F:transcription coregulator activity; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:1904385; P:cellular response to angiotensin; IMP:BHF-UCL.
DR   GO; GO:0071359; P:cellular response to dsRNA; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:BHF-UCL.
DR   GO; GO:0097398; P:cellular response to interleukin-17; IEA:Ensembl.
DR   GO; GO:0071354; P:cellular response to interleukin-6; IMP:BHF-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:MGI.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IMP:BHF-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0098586; P:cellular response to virus; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IDA:UniProt.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007254; P:JNK cascade; IEA:Ensembl.
DR   GO; GO:0060056; P:mammary gland involution; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010956; P:negative regulation of calcidiol 1-monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0032375; P:negative regulation of cholesterol transport; IC:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0051248; P:negative regulation of protein metabolic process; IC:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0010957; P:negative regulation of vitamin D biosynthetic process; IC:BHF-UCL.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IDA:UniProt.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:1900127; P:positive regulation of hyaluronan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0010884; P:positive regulation of lipid storage; IC:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IC:BHF-UCL.
DR   GO; GO:2000630; P:positive regulation of miRNA metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0034097; P:response to cytokine; IBA:GO_Central.
DR   GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:UniProtKB.
DR   CDD; cd08797; Death_NFkB1_p105; 1.
DR   CDD; cd01177; IPT_NFkappaB; 1.
DR   CDD; cd07935; RHD-n_NFkB1; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   Gene3D; 2.60.40.340; Rel homology domain (RHD), DNA-binding domain; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR033926; IPT_NFkappaB.
DR   InterPro; IPR047096; NF-kB_p105_DD.
DR   InterPro; IPR030503; NF-kB_p105_RHD_N.
DR   InterPro; IPR000451; NFkB/Dor.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR030492; RHD_CS.
DR   InterPro; IPR032397; RHD_dimer.
DR   InterPro; IPR011539; RHD_DNA_bind_dom.
DR   InterPro; IPR037059; RHD_DNA_bind_dom_sf.
DR   PANTHER; PTHR24169:SF9; NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT; 1.
DR   PANTHER; PTHR24169; NUCLEAR FACTOR NF-KAPPA-B PROTEIN; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF16179; RHD_dimer; 1.
DR   Pfam; PF00554; RHD_DNA_bind; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   PRINTS; PR00057; NFKBTNSCPFCT.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00429; IPT; 1.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF81296; E set domains; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 5.
DR   PROSITE; PS01204; REL_1; 1.
DR   PROSITE; PS50254; REL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; ANK repeat;
KW   Apoptosis; Cytoplasm; Direct protein sequencing; DNA-binding;
KW   Hydroxylation; Isopeptide bond; Lipoprotein; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; S-nitrosylation; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..968
FT                   /note="Nuclear factor NF-kappa-B p105 subunit"
FT                   /id="PRO_0000030310"
FT   CHAIN           1..433
FT                   /note="Nuclear factor NF-kappa-B p50 subunit"
FT                   /id="PRO_0000030311"
FT   DOMAIN          42..367
FT                   /note="RHD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00265"
FT   REPEAT          542..571
FT                   /note="ANK 1"
FT   REPEAT          581..610
FT                   /note="ANK 2"
FT   REPEAT          614..643
FT                   /note="ANK 3"
FT   REPEAT          650..679
FT                   /note="ANK 4"
FT   REPEAT          684..714
FT                   /note="ANK 5"
FT   REPEAT          718..747
FT                   /note="ANK 6"
FT   REPEAT          771..801
FT                   /note="ANK 7"
FT   DOMAIN          805..892
FT                   /note="Death"
FT   REGION          372..394
FT                   /note="GRR"
FT                   /evidence="ECO:0000269|PubMed:8628291"
FT   REGION          425..453
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..968
FT                   /note="Interaction with CFLAR"
FT                   /evidence="ECO:0000269|PubMed:13679070"
FT   REGION          650..684
FT                   /note="Essential for interaction with HIF1AN"
FT                   /evidence="ECO:0000269|PubMed:17003112"
FT   MOTIF           360..365
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        434..453
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            433..434
FT                   /note="Cleavage (when cotranslationally processed)"
FT                   /evidence="ECO:0000269|PubMed:9529257"
FT   MOD_RES         61
FT                   /note="S-nitrosocysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:8710491"
FT   MOD_RES         337
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         431
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000305|PubMed:11739381"
FT   MOD_RES         440
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000305|PubMed:11739381"
FT   MOD_RES         441
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000305|PubMed:11739381"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P25799"
FT   MOD_RES         678
FT                   /note="(3S)-3-hydroxyasparagine; by HIF1AN; partial"
FT                   /evidence="ECO:0000269|PubMed:17003112"
FT   MOD_RES         759
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63369"
FT   MOD_RES         892
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         903
FT                   /note="Phosphoserine; by GSK3-beta; in vitro"
FT                   /evidence="ECO:0000269|PubMed:12871932,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         907
FT                   /note="Phosphoserine; by GSK3-beta; in vitro"
FT                   /evidence="ECO:0000269|PubMed:12871932,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         923
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11158290"
FT   MOD_RES         927
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000269|PubMed:11158290,
FT                   ECO:0000269|PubMed:11297557, ECO:0000269|PubMed:12482991,
FT                   ECO:0000269|PubMed:25860612"
FT   MOD_RES         932
FT                   /note="Phosphoserine; by IKKB"
FT                   /evidence="ECO:0000269|PubMed:12482991"
FT   MOD_RES         937
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         943
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P25799"
FT   LIPID           61
FT                   /note="S-(15-deoxy-Delta12,14-prostaglandin J2-9-
FT                   yl)cysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:11466314"
FT   CROSSLNK        325
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..180
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042869"
FT   VAR_SEQ         39
FT                   /note="T -> TA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:2203531"
FT                   /id="VSP_021025"
FT   VAR_SEQ         181..189
FT                   /note="EGGGDRQLG -> MNGLCCMAL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042870"
FT   VARIANT         489
FT                   /note="T -> I (in dbSNP:rs4648065)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_016268"
FT   VARIANT         506
FT                   /note="M -> V (in dbSNP:rs4648072)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_016269"
FT   VARIANT         566
FT                   /note="T -> I (in dbSNP:rs4648085)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_016270"
FT   VARIANT         578
FT                   /note="R -> K (in dbSNP:rs4648086)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_016271"
FT   VARIANT         711
FT                   /note="H -> Q (in dbSNP:rs4648099)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_016272"
FT   VARIANT         901
FT                   /note="A -> T (in dbSNP:rs4648118)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_016273"
FT   MUTAGEN         61
FT                   /note="C->S: Suppresses S-nitrosylation-induced inhibition
FT                   of DNA-binding activity. Loss of
FT                   S-(15-deoxy-Delta12,14-prostaglandin
FT                   J2-9-yl)cysteine-induced inhibition of DNA-binding
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11466314,
FT                   ECO:0000269|PubMed:8710491"
FT   MUTAGEN         678
FT                   /note="N->A: Fails to promote HIF1AN-dependent
FT                   2-oxoglutarate decarboxylation."
FT                   /evidence="ECO:0000269|PubMed:17003112"
FT   MUTAGEN         903
FT                   /note="S->A: Prevents p105 proteolysis in response to
FT                   TNF-alpha."
FT                   /evidence="ECO:0000269|PubMed:12871932"
FT   MUTAGEN         907
FT                   /note="S->A: Prevents p105 proteolysis in response to
FT                   TNF-alpha."
FT                   /evidence="ECO:0000269|PubMed:12871932"
FT   MUTAGEN         921
FT                   /note="S->A: Decrease in stimuli-induced phosphorylation.
FT                   Loss of phosphorylation; when associated with A-923 and
FT                   A-932."
FT                   /evidence="ECO:0000269|PubMed:10469655"
FT   MUTAGEN         923
FT                   /note="S->A: Decrease in stimuli-induced phosphorylation.
FT                   Loss of phosphorylation; when associated with A-921 and
FT                   A-932."
FT                   /evidence="ECO:0000269|PubMed:10469655"
FT   MUTAGEN         927
FT                   /note="S->A: Decreased phosphorylation by IKBKB/IKKB and
FT                   decreased generation of the NF-kappa-B p50 subunit from
FT                   p105."
FT                   /evidence="ECO:0000269|PubMed:25860612"
FT   MUTAGEN         932
FT                   /note="S->A: Decrease in stimuli-induced phosphorylation.
FT                   Loss of phosphorylation; when associated with A-921 and
FT                   A-923."
FT                   /evidence="ECO:0000269|PubMed:10469655"
FT   CONFLICT        243
FT                   /note="K -> SE (in Ref. 4; CAB94757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        361
FT                   /note="R -> G (in Ref. 7; CAH18336)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        551..552
FT                   /note="II -> SS (in Ref. 4; CAB94757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        573
FT                   /note="D -> G (in Ref. 6; BAF84139)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        726
FT                   /note="A -> V (in Ref. 4; CAB94757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        825
FT                   /note="I -> T (in Ref. 7; CAH18336)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        869
FT                   /note="V -> I (in Ref. 4; CAB94757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        927
FT                   /note="S -> T (in Ref. 1; AAA36361, 3; AAA36360 and 4;
FT                   CAB94757)"
FT                   /evidence="ECO:0000305"
FT   STRAND          43..48
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          52..54
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           60..62
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          83..88
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          94..100
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          110..115
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          122..126
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          138..143
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           146..148
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           149..163
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           167..170
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           173..178
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:2O61"
FT   TURN            184..187
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           190..204
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          211..221
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          227..230
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          234..240
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           245..247
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          252..256
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          258..261
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          267..274
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          281..288
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   TURN            289..291
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          292..297
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           302..304
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   TURN            307..309
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          310..314
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          319..322
FT                   /evidence="ECO:0007829|PDB:2O61"
FT   STRAND          327..334
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   TURN            336..338
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   STRAND          345..350
FT                   /evidence="ECO:0007829|PDB:1SVC"
FT   HELIX           813..823
FT                   /evidence="ECO:0007829|PDB:2DBF"
FT   HELIX           832..839
FT                   /evidence="ECO:0007829|PDB:2DBF"
FT   HELIX           842..844
FT                   /evidence="ECO:0007829|PDB:2DBF"
FT   HELIX           845..850
FT                   /evidence="ECO:0007829|PDB:2DBF"
FT   HELIX           854..864
FT                   /evidence="ECO:0007829|PDB:2DBF"
FT   HELIX           869..879
FT                   /evidence="ECO:0007829|PDB:2DBF"
FT   HELIX           883..892
FT                   /evidence="ECO:0007829|PDB:2DBF"
SQ   SEQUENCE   968 AA;  105356 MW;  2A7C8FF86A10D1A8 CRC64;
     MAEDDPYLGR PEQMFHLDPS LTHTIFNPEV FQPQMALPTD GPYLQILEQP KQRGFRFRYV
     CEGPSHGGLP GASSEKNKKS YPQVKICNYV GPAKVIVQLV TNGKNIHLHA HSLVGKHCED
     GICTVTAGPK DMVVGFANLG ILHVTKKKVF ETLEARMTEA CIRGYNPGLL VHPDLAYLQA
     EGGGDRQLGD REKELIRQAA LQQTKEMDLS VVRLMFTAFL PDSTGSFTRR LEPVVSDAIY
     DSKAPNASNL KIVRMDRTAG CVTGGEEIYL LCDKVQKDDI QIRFYEEEEN GGVWEGFGDF
     SPTDVHRQFA IVFKTPKYKD INITKPASVF VQLRRKSDLE TSEPKPFLYY PEIKDKEEVQ
     RKRQKLMPNF SDSFGGGSGA GAGGGGMFGS GGGGGGTGST GPGYSFPHYG FPTYGGITFH
     PGTTKSNAGM KHGTMDTESK KDPEGCDKSD DKNTVNLFGK VIETTEQDQE PSEATVGNGE
     VTLTYATGTK EESAGVQDNL FLEKAMQLAK RHANALFDYA VTGDVKMLLA VQRHLTAVQD
     ENGDSVLHLA IIHLHSQLVR DLLEVTSGLI SDDIINMRND LYQTPLHLAV ITKQEDVVED
     LLRAGADLSL LDRLGNSVLH LAAKEGHDKV LSILLKHKKA ALLLDHPNGD GLNAIHLAMM
     SNSLPCLLLL VAAGADVNAQ EQKSGRTALH LAVEHDNISL AGCLLLEGDA HVDSTTYDGT
     TPLHIAAGRG STRLAALLKA AGADPLVENF EPLYDLDDSW ENAGEDEGVV PGTTPLDMAT
     SWQVFDILNG KPYEPEFTSD DLLAQGDMKQ LAEDVKLQLY KLLEIPDPDK NWATLAQKLG
     LGILNNAFRL SPAPSKTLMD NYEVSGGTVR ELVEALRQMG YTEAIEVIQA ASSPVKTTSQ
     AHSLPLSPAS TRQQIDELRD SDSVCDSGVE TSFRKLSFTE SLTSGASLLT LNKMPHDYGQ
     EGPLEGKI
//
